Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma - 27/07/19
Doi : 10.1016/j.path.2019.03.012
Keywords : DLBCL prognosis, Immunophenotype, Mutational profile
Esquema
| Disclosures: A. Dogan receives personal consultancy fees from Roche, Corvus Pharmaceuticals, Physicians' Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene, and Novartis, and research grants from National Cancer Institute, Roche. A. Chan has nothing to disclose. |
|
| Funded by: NIHHYB. Grant numbers: P30 CA008748; P50 CA192937. |
© 2019
Elsevier Inc. Reservados todos los derechos.
Vol 12 - N° 3
P. 699-707 - septembre 2019 Regresar al número
Artículo precedente
- Acute Leukemias of Ambiguous Lineage : Clarification on Lineage Specificity
- Jason H. Kurzer, Olga K. Weinberg
- Challenges in the Diagnosis of Gray Zone Lymphomas
- Kyle Parker, Girish Venkataraman
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?